ChemicalBook > CAS DataBase List > Morolimumab

Morolimumab

Product Name
Morolimumab
CAS No.
202833-07-6
Chemical Name
Morolimumab
Synonyms
Morolimumab;Research Grade Morolimumab;Research Grade Morolimumab (DHF92102)
CBNumber
CB68080804
Formula Weight
0
MOL File
Mol file
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

Morolimumab Chemical Properties,Usage,Production

Uses

Morolimumab is an IgG1 human anti-RHD/CD240D monoclonal antibody. Morolimumab can be used for the research of immune disease[1].

References

[1] Xiao, Tengfei, et al. Antibody compositions and methods for treating autoimmune diseases and cancers by targeting IGSF8. WO2023018722. 2022.

Morolimumab Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Morolimumab Suppliers

ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Fax
QQ:2853530913
Email
2853530910@QQ.com
Country
China
ProdList
8000
Advantage
62
Wuhan Chemstan Biotechnology Co., Ltd.
Tel
027-65317797 15926423062
Fax
QQ:422450190
Email
422450190@qq.com
Country
China
ProdList
10308
Advantage
58
Biolab Reagents
Tel
027-65279366 18108604356
Email
products@biolabreagent.com
Country
China
ProdList
9868
Advantage
58
Shanghai Yifei Biotechnology Co. , Ltd.
Tel
021-65675885 18964387627
Email
customer_service@efebio.com
Country
China
ProdList
11973
Advantage
58
Atagenix Laboratories
Tel
027-87008169 17762441161
Email
info@atagenix.com
Country
China
ProdList
10001
Advantage
58
AntibodySystem Laboratories SAS
Tel
33175446423
Email
support@antibodysystem.com
Country
China
ProdList
6739
Advantage
58
Biosynth Biological Technology (Suzhou) Co Ltd
Tel
51288865780
Email
sales@biosynth.com
Country
China
ProdList
6051
Advantage
58
Cell Sciences
Tel
9785721070
Email
info@cellsciences.com
Country
China
ProdList
6308
Advantage
58
Guangzhou Chuangze Biotechnology Co., Ltd.
Tel
18312220236
Country
CHINA
ProdList
178
Advantage
58

202833-07-6, MorolimumabRelated Search:


  • Morolimumab
  • Research Grade Morolimumab (DHF92102)
  • Research Grade Morolimumab
  • 202833-07-6